Moreover, in order to make better clinical decisions regarding appropriate treatments for HNSCC, identification of tumour areas with activated TGF-β signalling pathway would help pathologist to assess clinical risks for metastasis, recurrence, and chemoresistance in HNSCC. This evidence concerns the gene TGFB1 and neoplasm.